Chinese Robotics Stocks React as Humanoid Robot Marathon Sparks Competition Concerns 
Jeff Bezos Eyes $10 Billion Funding Round for AI Venture Project Prometheus 
Florida Launches Criminal Probe Into OpenAI Over FSU Shooting Incident 
Tesla Earnings Beat Expectations as EV Growth Holds Amid Robotics and AI Shift 
Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
OPmobility Reports Q1 Revenue Dip Amid Automotive Industry Slowdown 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
SK Hynix Reports Record Q1 Profit Surge Driven by AI Memory Chip Demand 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
China Food Delivery Stocks Dip as Regulators Crack Down on “Ghost Deliveries” 
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal 
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
Nidec Stock Rises After Accounting Probe Report Eases Delisting Concerns 
Meta Expands AI Training With Employee Activity Tracking Tools 
TEL AVIV, Israel, March 15, 2017 -- VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced it will provide a corporate overview at the Oppenheimer 27th Annual Healthcare Conference, being held March 21-22, 2017 at the New York Grand Central Hotel in New York City.
| VBL Therapeutics Presentation Details @ Oppenheimer 27th Annual Healthcare Conference | |
| Date: | Wednesday, March 22 |
| Time: | 9:10am Eastern Time |
| Presentation Room: | Track #3 |
About VBL
Vascular Biogenics Ltd., operating as VBL Therapeutics, is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for cancer. The Company’s lead oncology product candidate, ofranergene obadenovec (VB-111), is a first-in-class, targeted anti-cancer gene-therapy agent that is positioned to treat a wide range of solid tumors. It is conveniently administered as an IV infusion once every two months. It has been observed to be well-tolerated in >200 cancer patients and we have observed its efficacy signals in an “all comers” Phase 1 trial as well as in three tumor-specific Phase 2 studies. Ofranergene obadenovec is currently being studied in a Phase 3 pivotal trial for recurrent Glioblastoma, conducted under an FDA Special Protocol Assessment (SPA).
INVESTOR CONTACT: Michael Rice LifeSci Advisors, LLC (646) 597-6979
